Acute lower respiratory tract infections are the leading cause of death in children under the age of 5, killing more than 4 million children worldwide each year. Moreover, it is estimated that about 15 million premature babies are born in the world each year and 73% of them will need oxygen therapy.

Oxygen is a critical treatment for many newborn and childhood conditions. However, prolonged oxygen administration often comes with unpleasant side effects that can lead in almost 68% of cases to complications such as nasal dryness, nosebleeds, skin irritation and even septal cartilage necrosis due to pressure.

**OUR SOLUTION**

Novel improved pacifier with a simple and compact configuration to provide a reliable retention of the nasal cannula in an optimal position for efficient oxygen therapy. Our asset comprises a support device that can be easily attached to any conventional pacifier and is suitable for neonates and children.

Our asset may overcome most of the drawbacks of pediatric oxygen therapy through nasal cannula. The design allows correct administration of oxygen, avoiding contact with the cannula and reducing related complications.

**THE ASSET**

- Mechanism of action: Support device for nasal cannula oxygen administration
- Potential indications: Improve oxygen therapy in neonates and children
- IP Protection: EP22382508

**MARKET**

- Market size: 22,8M devices per year
- Market value: €130M with expected CAGR of 7,5%
- Market growth: Increase of birth complications rates, growth of number of respiratory diseases and rise of premature birth rates

**ADVANTAGES**

- Non-invasive oxygen therapy
- Both hospital and home use
- Suitable for neonates, infants and children
- Adaptable to multiple commercial nasal cannula
- Affordable and cost-effective
- Flexible and soft design

**OPPORTUNITY**

- License out
- Co-development

**CONTACT**

innovation@igt.cat
Innovation & Business Development Unit

**INNOVATION**

Germans Trias i Pujol Research Institute